Filtros de búsqueda

Lista de obras de Aurélien Marabelle

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

artículo científico publicado en 2017

A tribute to the life and career of Holbrook Kohrt

artículo científico publicado en 2016

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

artículo científico publicado en 2017

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

artículo científico publicado en 2008

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

artículo científico publicado en 2017

Biomarkers associated with checkpoint inhibitors

artículo científico publicado en 2016

CD34+ immunoselection of autologous grafts for the treatment of high‐risk neuroblastoma ⬇️

artículo científico publicado el 1 de enero de 2011

Cabergoline therapy of paraneoplastic Cushing syndrome in children

artículo científico publicado en 2010

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

artículo científico publicado en 2017

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

artículo científico publicado en 2015

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

artículo científico publicado en 2016

Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy

scientific article published on 04 September 2020

Clear cell ependymoma with trisomy 19 developing bone metastases

artículo científico publicado en 2011

Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.

artículo científico publicado en 2014

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

artículo científico publicado en 2015

Combination strategies to enhance antitumor ADCC.

artículo científico publicado en 2012

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

artículo científico publicado en 2013

Depleting tumor-specific Tregs at a single site eradicates disseminatedtumors.

artículo científico publicado en 2013

Design and conduct of early clinical studies of immunotherapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

artículo científico publicado en 2020

Detection of tumor ALK status in neuroblastoma patients using peripheral blood

artículo científico publicado en 2015

Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer

artículo científico publicado en 2022

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

artículo científico publicado en 2020

Focal nodular hyperplasia of the liver in patients previously treated for pediatric neoplastic diseases

artículo científico publicado en 2008

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

artículo científico publicado en 2017

Holbrook Kohrt: In Memoriam (1977-2016).

artículo científico publicado en 2016

Hypercalcemia and 13-cis-retinoic acid in post-consolidation therapy of neuroblastoma

artículo científico publicado en 2009

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine

artículo científico

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

artículo científico publicado en 2016

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

artículo científico publicado en 2017

Immune responses during COVID-19 infection

scientific article published on 25 August 2020

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

artículo científico publicado en 2016

Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine

artículo científico publicado en 2012

Immunodynamics of explanted human tumors for immuno-oncology

artículo científico publicado en 2020

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

artículo científico publicado en 2016

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop

artículo científico publicado en 2016

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

artículo científico publicado en 2016

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

artículo científico publicado en 2020

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

artículo científico publicado en 2018

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer

artículo científico publicado en 2015

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: Reactivation of tuberculosis after anti PD-1 treatment

artículo científico publicado en 2017

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

artículo científico publicado en 2017

Interventional radiology for local immunotherapy in oncology

artículo científico publicado en 2021

Intratumoral Immunotherapy: from Trial Design to Clinical Practice

scientific article published on 17 September 2020

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity

artículo científico publicado en 2013

Intratumoral immunization: a new paradigm for cancer therapy

artículo científico publicado en 2014

Intratumoral immunotherapy: using the tumor as the remedy

artículo científico publicado en 2017

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer

artículo científico publicado en 2017

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

artículo científico publicado en 2018

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

artículo científico publicado en 2015

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.

artículo científico publicado en 2016

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

artículo científico publicado en 2016

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

artículo científico publicado en 2016

New insights into the mechanism of action of immune checkpoint antibodies

artículo científico publicado en 2014

Paradigm shift in oncology: targeting the immune system rather than cancer cells

artículo científico publicado en 2015

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection

scientific article published on 23 May 2019

Pattern recognition receptors: immune targets to enhance cancer immunotherapy

artículo científico publicado en 2017

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

artículo científico publicado en 2017

Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination

artículo científico publicado en 2020

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies

artículo científico publicado en 2020

Predictors of responses to immune checkpoint blockade in advanced melanoma

artículo científico publicado en 2017

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

artículo científico publicado en 2017

Prime time for immune-checkpoint targeted therapy at ASCO 2015

artículo científico publicado en 2016

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer

scientific article published on 13 May 2016

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

artículo científico publicado en 2021

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

artículo científico publicado en 2017

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy

artículo científico publicado en 2016

Rationale for anti-OX40 cancer immunotherapy

artículo científico publicado en 2015

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade

scientific article published on 01 October 2019

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

artículo científico publicado en 2017

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

artículo científico publicado en 2020

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

artículo científico publicado en 2018

Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues

artículo científico publicado en 2016

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

scientific article published on 03 September 2019

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

artículo científico

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

artículo científico

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

artículo científico publicado en 2016

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

artículo científico publicado en 2016

The oncolytic compound LTX-401 targets the Golgi apparatus

artículo científico publicado en 2017

The oncolytic compound LTX-401 targets the Golgi apparatus.

artículo científico publicado en 2016

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

artículo científico publicado en 2016

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

artículo científico publicado en 2015

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

artículo científico publicado en 2015

Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy

artículo científico publicado en 2015

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

artículo científico publicado en 2016

Two cases of immune thrombocytopenia associated with pembrolizumab.

artículo científico publicado en 2015

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda